It's not useful to them. And even if it was, they'd be breaking half a dozen rules at the risk of getting the whole study trashed and billions lost, for almost

It's not useful to them. And even if it was, they'd be breaking half a dozen rules at the risk of getting the whole study trashed and billions lost, for almost no benefit. Getting a study invalidated is the nightmare scenario of every pharma company. And it's not just the FDA or EMEA but also scientific journals that go through this stuff.